MOSHE TALPAZ, M.D.; GIORA MAVLIGIT, M.D.; MICHAEL KEATING, M.D.; RONALD S. WALTERS, M.D.; JORDAN U. GUTTERMAN, M.D.
Nine patients with refractory chronic myelogenous leukemia and severe symptomatic thrombocytosis (≥ 1 x 106 platelets/mm3) were given partially purified human leukocyte interferon-alpha. A significant decline in platelet counts, from a mean (> SE) of 1.71 ± 0.53 x 106/mm3 to a mean of 0.52 ± 0.24 x 106/mm3 (p < 0.01), resulted in all patients. Maintenance of low platelet counts was achieved in two patients for more than 143 and 300 days, respectively. Treatment with human leukocyte interferon-alpha was stopped in the remaining patients because of increases in the leukocyte count, toxicity, or both. Our preliminary observations suggest that human leukocyte interferon-alpha may significantly alleviate progressive thrombocytosis in advanced chronic myelogenous leukemia. Further studies of human leukocyte interferon-alpha and chemotherapeutic agents are indicated.
MOSHE TALPAZ, GIORA MAVLIGIT, MICHAEL KEATING, RONALD S. WALTERS, JORDAN U. GUTTERMAN. Human Leukocyte Interferon to Control Thrombocytosis in Chronic Myelogenous Leukemia. Ann Intern Med. 1983;99:789–792. doi: 10.7326/0003-4819-99-6-789
Download citation file:
Published: Ann Intern Med. 1983;99(6):789-792.
Hematology/Oncology, Leukemia/Lymphoma, Platelet Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use